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Abstract
Background Pituitary tumours are usually benign and relatively common intracranial tumours, with under- and over-
expression of pituitary hormones and local mass effects causing considerable morbidity and increased mortality. While most
pituitary tumours are sporadic, around 5% of the cases arise in a familial setting, either isolated [familial isolated pituitary
adenoma, related to AIP or X-linked acrogigantism], or in a syndromic disorder, such as multiple endocrine neoplasia type 1
or 4, Carney complex, McCune–Albright syndrome, phaeochromocytoma/paraganglioma with pituitary adenoma,
DICER1 syndrome, Lynch syndrome, and USP8-related syndrome. Genetically determined pituitary tumours usually present
at younger age and show aggressive behaviour, and are often resistant to different treatment modalities.
Subject In this practical summary, we take a practical approach: which genetic syndromes should be considered in case of
different presentation, such as tumour type, family history, age of onset and additional clinical features of the patient.
Conclusion The identification of the causative mutation allows genetic and clinical screening of relatives at risk, resulting in
earlier diagnosis, a better therapeutic response and ultimately to better long-term outcomes.
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Introduction
Consideration of genetic abnormalities in a patient with a
pituitary tumour has only recently entered the clinical
thinking of the practising endocrinologist. While in families
with multiple endocrine neoplasia type 1 (MEN1) syndrome
it was long recognised that members can develop pituitary
adenomas with incomplete penetrance, the flurry of condi-
tions we can now list with a genetic cause of pituitary
adenoma would have been well beyond imagination 20
years ago. Indeed, most pituitary tumours are sporadic, but
approximately 5% can be due to a hereditary disease.
Pituitary tumours can occur in a familial setting, either
isolated [Familial Isolated Pituitary Adenoma (FIPA), for
example aryl hydrocarbon receptor-interacting protein (AIP)
mutation-positive FIPA, or in patients with X-linked acro-
gigantism (XLAG)], or as part of a syndromic condition,
such as MEN1 or MEN4, Carney complex (CNC),
McCune–Albright syndrome (MAS), phaeochromocytoma/
paraganglioma with pituitary adenoma (3P associations,
3Pa), DICER1 syndrome and a USP8-related syndrome and
some other rare conditions where the nature of association
with pituitary adenomas needs further studies (Table 1).
Genetic testing might lead to the recognition of a syn-
dromic disease and therefore beneficial effects of timely
identification of other aspects of the disease, or it can
diagnose disease in family members at an early stage
leading to earlier diagnosis and treatment, and ultimately to
better outcomes.
Here we approach this issue from the practical point of
view, centring the discussion on the presentation of the
patient.
Gigantism
The most common cause of a germline genetic abnormality
in a patient with a pituitary adenoma is growth hormone
(GH) excess, especially childhood-onset GH excess leading
to gigantism. While the usual cause of acromegalic
gigantism is a GH-secreting pituitary adenoma, resulting in
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elevated GH- and insulin-like growth factor 1 (IGF-1)
levels, we should remember other conditions with tall sta-
ture, either as a normal variant or part of a syndrome with
no abnormalities in the GH axis [1].
For true acromegalic gigantism we need to consider the
age of onset of rapid growth. In case of very early onset,
XLAG (<2 years of age) and MAS (from 3 years of age)
might be the diagnosis.
XLAG is an infant-onset gigantism syndrome caused
by germline or somatic mosaic duplication of the GPR101
gene, which encodes a G-protein coupled receptor [2, 3].
The onset of accelerated growth is always observed before
the age of 5 years, and in most patients during the first
year of life. Apart from rapid growth, these children have
acromegalic features, such as acral enlargement and facial
coarsening and other abnormalities, like increased appe-
tite and hyperinsulinemia [4]. Their pituitary MRI can
show a tumour, a diffusely enlarged gland suggesting
hyperplasia or a normal MRI. The tumours often have an
unusual histological appearance (sinusoidal, lobular and
acinar architecture, microcalcification and pseudo-
follicles are characteristic), while hyperplasia can be
seen on histology in some cases [3]. Pituitary hyperplasia
can be also observed in same cases of MAS, CNC and in
GH-releasing hormone (GHRH)-induced GH excess.
GPR101 variants, other than gene duplication, have not
been associated with GH-secreting or other type of
pituitary tumours [3, 5–8].
AIP-related gigantism is the most common genetic cause
of pituitary gigantism [3, 9]. Patients typically show signs
of the disease during the second decade but several cases
have been described with accelerated growth already in the
first decade. These patients usually have large invasive
tumours needing multiple treatment modalities [10, 11],
although microadenoma cured after surgery has also been
described [12]. Pituitary apoplexy is a characteristic phe-
nomenon in some AIP mutation-positive patients [11–13].
Male predominance is observed in AIP mutation-positive
gigantism, although the physiologically later puberty and
ascertainment bias due to taller stature in males could play a
part in this.
MEN1 syndrome extremely rarely manifests as gigant-
ism. A 5-year-old boy was described with a mammoso-
matotroph macroadenoma causing gigantism [14], while
another case of MEN1-related gigantism was due to a
pancreatic GHRH-secreting tumour [15].
MAS is a mosaic disease, caused by a mutation in the
GNAS gene at an early post-zygotic stage of development.
The variable phenotype depends on what tissues are affec-
ted by the mutation. MAS is characterised by fibrous dys-
plasia, cafè-au-lait spots of the skin and different
endocrinopathies. Acromegaly affects around 20% of MAS
patient. The mean age at diagnosis of acromegaly is 24.4
years; however, the disease can start in early childhood as
well [16].
In the case of disease onset at >3 years of age but still in
childhood, AIP, MEN1 and 4, CNC, MAS, 3Pa and a non-
pituitary condition neurofibromatosis type 1 (NF1), should
be considered. In NF1, approximately 10% of cases with
optic glioma have GH excess often manifesting in child-
hood and causing accelerated growth; the exact mechanism
of the GH excess is unknown (Fig. 1).
Acromegaly
Apart from age of onset, the other major significant fea-
ture for GH excess patients is the family history. A
positive family history is very suggestive of a genetic
disease, but we should be aware of phenocopies—the
same phenotype by chance and not due to common
genetic background; this has been described in several
AIP- and succinate dehydrogenase (SDHx)-positive
families already [17–19]. In the case of a positive family
history, the most common diseases are related to AIP or
MEN1 mutations. If there is no family history of pituitary
tumours, this could be due to (i) a lack of genetic
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background, (ii) low penetrance, (iii) lack of information
regarding a positive family history, (iv) a de novo germ-
line or mosaic mutation and (v) imprinting complicating
penetrance (SDHD for example).
FIPA is defined as two or more members of a family
who develop pituitary adenoma with no other clinical
manifestation. In FIPA families, either heterogeneous—
with different pituitary tumour subtypes, or homogeneous
—the most frequent pituitary adenoma subtypes are
somatotrophinomas or prolactinomas. Germline mutations
in the AIP gene have been identified in 10% of FIPA
families, while in most cases the causative gene(s) remain
unknown. It is important to note that AIP mutations can
also occur in subjects with apparently sporadic early-onset
somatotrophinomas or prolactinomas, as a consequence of
incomplete penetrance, while de novo mutations are
extremely rare. AIP mutation-positive tumours show a
distinct phenotype, with younger age at diagnosis (usually
age of onset under 30 years), tumour invasiveness and
relative resistance to treatment with first-generation
somatostatin receptor ligands. AIP mutation-positive
patients usually need a multimodal therapeutic approach.
In AIP mutation-negative patients somatotrophinoma is
also the most common subtype (although not as common
as in AIP mutation-positive subjects, around 78% com-
pared to 58%) [10, 12, 18].
MEN1 is an autosomal dominantly inherited disease
characterised by hyperparathyroidism, gastro-enteropancreatic
neuroendocrine (NET) and pituitary tumours, with associated
other endocrine and non-endocrine tumours. Mutations of the
MEN1 tumour suppressor gene are detected in 90% patients
with the MEN1 phenotype. De novo germline or mosaic
mutations occur in approximately 10% of cases. A pituitary
tumour develops in 30–40% of the patients [20]. Prolactino-
mas are the most common clinically presenting pituitary
tumour subtype, sometimes large and arising at a younger
age. Patients with MEN1 may have plurihormonal adenomas.
Non-functioning pituitary adenomas (NFPAs), somato-
trophinomas and, rarely, corticotrophinomas or thyro-
trophinomas have also been described. However, during
systematic screening of MEN1 mutation carriers, small non-
functioning lesions, not dissimilar to incidentalomas, can
often be found.
Around 10% of cases with a MEN1-like syndrome do
not have a mutation in MEN1. Some of these patients har-
bour germline changes in the CDKN1B gene coding for the
cyclin-dependent kinase inhibitor p27. This clinically
overlapping rare condition is termed MEN4 [21, 22]. In a
group of 24 patients with acromegaly and at least one other
manifestation of MEN1 syndrome, but without pathogenic
MEN1 or CDKN1B variants, a CDC73 missense mutation
was found in one case [23].
In cases of the MEN1 syndrome, a GHRH-secreting
pancreatic [24] or thymic [25] NET tumour might be part of
the syndrome and the source of GHRH, which causes
pituitary hyperplasia and thus acromegaly. A similar case
has now been described in a patient with germline MAX
mutation and multiple tumours including a GHRH-positive
phaeochromocytoma [26].
CNC is a clinical diagnosis based on characteristic skin
pigmentation, cardiac myxomas, primary pigmented nodu-
lar adrenocortical disease and pituitary tumour or hyper-
plasia, testicular lesions, melanotic schwannomas and
others. Although around 75% of patients have an abnormal
GH axis in CNC, only 10% of the patients show clinically
acromegaly, and less frequently gigantism. Most patients
(67%) have pituitary hyperplasia affecting the somato-
lactotroph cells, while only 10–12% of them have a real
GH-producing pituitary tumour [27]. Genetic testing for













































Fig. 1 Diseases to be considered
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regulatory subunit 1-α (PRKAR1A) coding gene is avail-
able, and large deletions are known to cause more severe
disease. There is a second locus located at 2p16, which is
still unknown, but cytogenetic changes of the 2p16 chro-
mosomal region are frequently observed in tumours from
CNC patients [28, 29].
Phaeochromocytoma/paraganglioma can be associated
with pituitary tumours (the 3Pa), even carcinoma [30], due
to mutations in SDHx or MAX genes. The pituitary tumours
include somatotrophinomas, prolactinomas and NFPAs.
Recently MAX mutation has been described in families with
phaeochromocytoma, pituitary adenoma and other endo-
crine- and non-endocrine tumours [26]. Acromegaly asso-
ciated with phaeochromocytoma can be the consequence of
a GHRH-secreting phaeochromocytoma without any pitui-
tary adenoma [19, 31] (Table 2).
NF1-associated GH excess should be considered in
patients with characteristic clinical signs and symptoms
of dermal neurofibromas, café-au-lait spots, axillary or
inguinal freckling and hamartomas of the iris as well as
brain neoplasms due to inactivating mutation of NF1
gene. Around 10% of children with NF1 and optic
pathways glioma show GH excess [32]. While tuberous
sclerosis has been described with pituitary adenomas,
the causative link between the two diseases is uncertain
[33, 34].
Acromegalic features and GH hypersecretion have been
recently described in patients with mutations in the X-linked
immunoglobulin superfamily member 1 (IGSF1) gene. The
exact mechanism of GH excess is unclear [35].
Somatic mutations can lead to acromegaly as well. The
most frequent genetic alteration is somatic GNAS mutation,
found in 40% of somatotrophinomas [36]. These tumours
show favourable clinical features, such as older age at
diagnosis, less invasiveness and better response to therapy
(Fig. 2).
Prolactinoma
Prolactinomas are the most common pituitary adenoma
subtype in MEN1, and the second most common in MEN4
and FIPA, both in AIP-positive (even as a homogenous
prolactinoma family [37]) and AIP-negative FIPA, but can
occur in SDHx cases as well (Fig. 3). Metastatic prolacti-
noma case has been described in MEN1 [38]. A large
childhood-onset prolactinoma can be the first manifestation
of MEN1 or AIP-related disease. Recently, two families
with MAX mutations with multiple tumour types were
described, including a patient with prolactinoma and para-
thyroid tumour in one of them [26].
Recently, a somatic mutation in the SF3B1 gene has been
described in 20% of prolactinoma patients, showing higher
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Cushing’s disease
Infant-onset Cushing’s disease can occur in
DICER1 syndrome with very low penetrance due to a
pituitary blastoma, but this is pathognomic to the dis-
ease. Pituitary blastomas are aggressive tumours arising
in young children, presenting clinically with often severe
ACTH-dependent hypercortisolism. It is locally
destructive, severe disease with high mortality [40]. A
family history of young-onset large goitre, pleur-
opulmonary blastoma, Sertoli–Leydig cell tumours,
nodular thyroid hyperplasia or differentiated cancer of
the thyroid, cystic nephroma and renal sarcoma can be
associated [41]. Cushing’s disease is rare (5–10%) in
MEN1 [42], and to date no convincing AIP mutation-
positive patient has been found with a cortico-
trophinoma. More recently, a few cases of CDKN1B
mutations were described in children with
corticotrophinoma with or without other features of
MEN4 [43]. Germline potentially pathogenic CABLES1
variants were identified in 2% of the cases in a patient
cohort of Cushing’s disease [44]. Aggressively growing
corticotroph tumours has been described as part of Lynch
syndrome in patients with DNA mismatch repair genes
MSH6, PMS2 mutations and associated colorectal,
endometrial, ovarian, urinary tract, small bowel, gastric,
hepatobiliary, adrenocortical or malignant brain tumours
[45]. Cushing’s disease has been described in patients
with RET mutation as part of MEN2A or MEN2B syn-
drome. It is unclear whether these cases are coin-
cidences, or RET mutation plays a causative role in
pituitary tumour formation ([46, 47] and references
within [19]).
Somatic USP8 mutations can be observed in cortico-
trophinomas in a high (around 30%) percentage. Patients




















































Fig. 2 Diseases to be considered
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Fig. 3 Diseases to be considered
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female, and they have more frequently microadenomas with
better therapeutic outcome [48, 49]. Germline USP8
mutation has been found in a paediatric case with recurrent
Cushing’s disease and developmental delay, representing a
syndromic form of pituitary adenomas [50]. Somatic GNAS
mutation might occur very rarely in ACTH-producing
pituitary adenomas [51, 52]. The differential diagnosis of
Cushing’s syndrome is often challenging, but two recent
case reports complicated this further in CNC: in addition to
the typical adrenal Cushing’s syndrome, pituitary Cushing’s
disease have been also described [53, 54]. Recently
aggressive corticotroph pituitary tumours and carcinomas
harbouring somatic mutations in ATRX [55] have been
described (Table 2) (Fig. 4).
Non-functioning pituitary adenoma
NFPAs can occur in MEN1 and mostly AIP mutation-
negative FIPA patients. NFPA can be part of AIP mutation-
negative homogenous NFPA kindreds—12% in our cohort
of 318 FIPA kindreds, or part of heterogenous families—
31% in our AIP mutation-negative cohort. AIP mutation-
positive clinically NFPA cases are often microadenomas
identified in asymptomatic carriers or if operated show
positive GH and PRL immunostaining [56]. NFPA might be
part of the 3Pa as well, and interestingly, the pituitary car-
cinoma case with an SDHB mutation was a non-functioning
pituitary tumour [30]. NFPAs are most often clinically silent
tumours, most often of gonadotroph origin (Fig. 5).
Thyrotrophinoma
TSH-producing pituitary tumours are very rare in a familial
setting. There is one case described with an AIP mutation
and a few cases with MEN1 mutation [57] including an
MEN1 mutation-positive metastatic case [58]. In
MEN1 syndrome PIT1-positive plurihormonal adenomas
can also be identified, sometimes with silent or clinically
relevant TSH positivity [59–61]. Somatic mutation has been
described in TRβ (THRB) [62] and a patient with TSHoma
and germline THRB mutation [63], corresponding to data
from a THRB-deficiency animal model where TSH-
secreting adenomas have been observed [64] (Fig. 6).
Clinical considerations
Pituitary tumours in a familial setting are relatively rare
disorders, and identification of the genetic cause can lead to
several advantages. Discovery of a syndromic disease might
help to identify other aspects of the proband’s condition
with beneficial effects through earlier treatment. Genetic
screening might help to identify family members in an
earlier stage of the disease, when the tumour responds better
to therapy and a better outcome can predicted.
First of all, a detailed family history should be obtained
from all patients with a pituitary tumour. In case of FIPA,
screening for AIP mutations should be considered, as
mutations are identified in about 10% of unselected families
and 20% of those with familial acromegaly. Screening for
AIP mutations should also be considered in patients, pri-
marily with GH or prolactin-secreting adenomas, with age
at onset ≤18 years and patients with macroadenomas and
age at onset ≤30 years. Genetic and clinical screening show
clear benefits in AIP mutation-positive patients; pro-
spectively diagnosed patients have smaller, less invasive
lesions controlled less frequently with multimodal treat-
ment, compared with clinically presenting patients [65].
XLAG should also be considered in case of early-onset
gigantism starting during the first 2 years of life.
In the case of MEN1, the additional main clinical fea-
tures, such as hyperparathyroidism and enteropancreatic
NET present in the proband or other family members, can
help in the decision regarding genetic testing. However,
pituitary tumours may represent the first disease manifes-
tation, and considering the possibility of de novo mutations,
screening for MEN1 should be considered in patients with
childhood-onset pituitary macroadenomas (especially pro-
lactinomas) [66]. In patients with a MEN1 phenotype but
without MEN1 mutation, the rare MEN4 should be con-
sidered and genetic testing for CDKN1B mutation is sug-
gested. Case reports of patients with multiple endocrine
tumours and CDC73 or MAX variants have been described.
Other less frequent syndromes should be considered in
the presence of associated features, such as testing for SDHx
mutation in case of phaeochromocytoma/paraganglioma
with pituitary adenoma or testing for PRKAR1A in case of
symptoms characteristic of CNC.
For patients with pituitary diseases there are a few
questions to consider:
● Which patient needs genetic testing?
Genetic testing is recommended in patients (i) with a
family history of pituitary tumour, (ii) with early-onset
pituitary tumour and (iii) with additional clinical
features which predispose to pituitary tumour in a
syndromic setting.
● What change will bring a genetic diagnosis in the
treatment or the follow-up of the proband?
Identifying a mutation helps to understand the nature
of the disease and be more vigilant regarding tumour
behaviour, can draw attention to possible hyperplasia,
but in general would not necessarily change the
treatment algorithm of the proband.
● Which family members need genetic screening?
Genetic testing should be offered to first-degree
668 Endocrine (2021) 71:663–674
relatives (children, siblings and parents) of a gene
carrier.
● How should carrier family members be followed up?
It depends on the specific syndromic condition, but in
general baseline clinical, biochemical and imaging
assessment is needed with follow-up depending on the
specific syndrome and patient age.




























Fig. 4 Diseases to be considered
in cases of Cushing’s disease.
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Fig. 5 Diseases to be considered
in cases of non-functioning
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Fig. 6 Diseases to be considered in cases of thyrotrophinomas. AIP
aryl hydrocarbon receptor-interacting protein, AIPneg-FIPA AIP
mutation-negative Familial Isolated Pituitary Adenoma (this group
does not represent XLAG families), FIPA Familial Isolated Pituitary
Adenoma, MEN multiple endocrine neoplasia, THRB thyroid hor-
mone receptor beta. *Case reports/further study needed [62, 63]
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monitor growth starting in early childhood and yearly
biochemical testing (GH, IGF-1 and prolactin) not later
than at the age of 10 years. A baseline pituitary MRI is
advised around the age of 10 and should be repeated
every 5 years until the age of 30, although between 20
and 30 follow-up could be gradually relaxed to facilitate
patient cooperation. In carriers identified as adults, if a
baseline clinical and biochemical assessments with
pituitary MRI has not identified any abnormality, then
screening can be reduced after the age of 30, as most
patients with AIP mutation start their disease before
this age.
In case of MEN1 patients, published guidelines
should be followed. For pituitary disease, starting at
the age of 5 with yearly clinical and biochemical
assessments (prolactin and IGF-1). A pituitary MRI
should be performed every 3 years [67, 68].
● If the categorisation of an identified variant is unclear,
i.e., a variant of uncertain significance, what policy
should be followed for the proband and family members?
In this case, genetic testing of family members is not
recommended. However, attention should be focused on
any family member developing typical signs or symptoms;
that person should be clinically evaluated, and if affected,
genetic testing performed. As data on genetic variants are
constantly evolving, patients and their clinicians should be
later notified if the status of the variant has changed based
on novel clinical, experimental or genetic data.
In conclusion, genetic testing not only helps us to iden-
tify patients with an increased risk of developing pituitary or
other tumours, and to achieve early diagnosis and better
therapeutic outcome, but also leads to better understanding
of pituitary tumorigenesis.
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